← Leaderboards
Christine Eng
Mount Sinai School Of Medicine Of Cuny
$10,462,016
Attributed
$10,462,016
Total exposure
16
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.7M · FY2005–21$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$10,462,016 · 16
By mechanism
U01$10,153,962 · 2
M01$308,054 · 14
Top collaborators
No co-investigators on record.
Most similar at Mount Sinai School Of Medicine Of Cuny
Same institution · by research overlap
- Pramod K Mistry$2,098,085
- Terry Francis Davies$14,158,538
Others in their field
Top investigators on “Institution”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,187,810,557
- Leonard Freedman · Leidos Biomedical Research, Inc.$835,530,754
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Jeffrey P Krischer · University Of South Florida$566,554,288
- Bambra Strokes · Ppd Development Lp$526,656,217
Research focus
InstitutionSyndromeEnrollmentMutationLaboratoriesProtocols DocumentationVariantSiteSpecific Qualifier ValueEvaluationGenome SequencingCost EffectiveCore FacilityExtramural ActivitiesDna Sequencing FacilityGeneticInnovationExome SequencingDideoxy Chain Termination Dna SequencingAreaDiagnostic ProcedureEnvironmentDiagnosisClinical Research Site
Grant awards (32)
Clinical Sequencing Core Facility for the Undiagnosed Diseases Network (UDN)$951,000
U01 · FY2021 · HG · contact PI
Clinical Sequencing Core Facility for the Undiagnosed Diseases Network (UDN)$1,426,500
U01 · FY2020 · HG · contact PI
Clinical Sequencing Core Facility for the Undiagnosed Diseases Network (UDN)$1,893,492
U01 · FY2019 · HG · contact PI
Clinical Sequencing Core Facility for the Undiagnosed Diseases Network (UDN)$847,950
U01 · FY2019 · HG · contact PI
Clinical Sequencing Core Facility for the Undiagnosed Diseases Network (UDN)$1,050,000
U01 · FY2018 · HG · contact PI
Clinical Sequencing Core Facility for the Undiagnosed Diseases Network$693,406
U01 · FY2017 · HG · contact PI
Clinical Sequencing Core Facility for the Undiagnosed Diseases Network$295,302
U01 · FY2017 · HG · contact PI
Clinical Sequencing Core Facility for the Undiagnosed Diseases Network$693,406
U01 · FY2016 · HG · contact PI
Clinical Sequencing Core Facility for the Undiagnosed Diseases Network$1,167,000
U01 · FY2015 · HG · contact PI
Clinical Sequencing Core Facility for the Undiagnosed Diseases Network$693,406
U01 · FY2015 · HG · contact PI
Clinical Sequencing Core Facility for the Undiagnosed Diseases Network$442,500
U01 · FY2014 · HG · contact PI
CLINICAL TRIAL: A MULTICENTER OPEN-LABEL STUDY OF GENE-ACTIVATED HUMAN GLUCOCERE$1,185
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: AN OPEN-LABEL EXTENSION OF STUDY TKT024 EVALUATING LONG-TERM SAF$2,900
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: A RANDOMIZED, OPEN-LABEL, STUDY TO ASSESS THE SAFETY AND TOLERAB$2,454
M01 · FY2008 · RR · contact PI
AN OPEN-LABEL EXTENSION OF STUDY TKT024 EVALUATING LONG-TERM SAFETY AND CLINI$42,177
M01 · FY2007 · RR · contact PI
EXPANDED ACCESS USE OF RECOMBINANT HUMAN ACID ALPHA-GLUCOSIDASE (RHGAA) (MYOZ$4,393
M01 · FY2007 · RR · contact PI
AN OPEN-LABEL EXTENSION OF STUDY TKT024 EVALUATING LONG-TERM SAFETY AND CLINI$77,233
M01 · FY2006 · RR · contact PI
IDURONATE-2-SULFATASE ENZYME REPLACEMENT THERAPY IN PATIENTS WITH MPS II$12,097
M01 · FY2006 · RR · contact PI
EXPANDED ACCESS USE OF RECOMBINANT HUMAN ACID ALPHA-GLUCOSIDASE (RHGAA) (MYOZ$8,065
M01 · FY2006 · RR · contact PI
MULTI-CENTER, OPEN LABEL STUDY OF THE SAFETY AND EFFICACY OF FABRAZYME IN PTS$4,962
M01 · FY2006 · RR · contact PI
IDURONATE-2-SULFATASE ENZYME REPLACEMENT THERAPY IN PATIENTS WITH MPS II$121,883
M01 · FY2005 · RR
STUDY OF THE SAFETY AND EFFICACY OF FABRAZYME IN FABRY PATIENTS$19,205
M01 · FY2005 · RR
Iduronate-2-Sulfatase Enzyme Replacement Therapy in MPS$8,519
M01 · FY2004 · RR
Phase 2, Randomized, Open-Label, Dose Ranging, Multiple Dose Study of Fabrazyme2$2,981
M01 · FY2004 · RR
RECOMBINANT ENZYME THERAPY FOR FABRY'S DISEASE$0
M01 · FY2002 · RR
OUTCOMES OF GENETIC TESTING AMONG ASHKENAZI FAMILIES$0
U01 · FY2002 · CA
SAFETY &EFFICACY OF RECOMBINANT ALPHA GALACTOSIDASE-A$0
M01 · FY2002 · RR
RECOMBINANT ENZYME THERAPY FOR FABRY'S DISEASE$0
M01 · FY2001 · RR
OUTCOMES OF GENETIC TESTING AMONG ASHKENAZI FAMILIES$0
U01 · FY2001 · CA
SAFETY &EFFICACY OF RECOMBINANT ALPHA GALACTOSIDASE-A$0
M01 · FY2001 · RR
RECOMBINANT ENZYME THERAPY FOR FABRY'S DISEASE$0
M01 · FY2000 · RR
SAFETY &EFFICACY OF RECOMBINANT ALPHA GALACTOSIDASE-A$0
M01 · FY2000 · RR